A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
for
Hidradenitis Suppurativa
Location: Boston MA, Sherbrooke, The Bronx NY, Montreal,
Sponsor: Sanofi
Sex: All
Age: 18+
Code: NCT07225569
Phase 2, Recruiting
Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
for
Sickle Cell Disease
Location: New Brunswick NJ, Atlanta GA, Omaha NE, Houston TX
Sponsor: Sanofi
Sex: All
Age: 2 - 17
Code: NCT07247188
Phase 3, Recruiting
A Longitudinal, Observational Study Comparing Real-World Experiences of Teplizumab-Treated and Untreated Participants With Stage 2 Type 1 Diabetes in the United States
for
Type 1 Diabetes
Location: San Francisco CA
Sponsor: Sanofi
Sex: All
Age: 8+
Code: NCT07260110
Recruiting
Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above.
for
Healthy Volunteers, Influenza
Location: Charlottesville VA, Rochester NY, Coral Gables FL,
Sponsor: Sanofi
Sex: All
Age: 18+
Code: NCT07779408
Phase 1, Phase 2, Recruiting
Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
for
Factor VIII Deficiency
Location: Hamilton, Indianapolis IN, Iowa City IA, Seattle WA
Sponsor: Sanofi
Sex: All
Age: 12+
Code: NCT06941870
Phase 4, Recruiting
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
for
Chronic Graft Versus Host Disease
Location: Boston MA, New York NY, Washington D.C. DC, Toronto,
Sponsor: Sanofi
Sex: All
Age: 1 - 18
Code: NCT07116031
Phase 2, Recruiting
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
for
Hidradenitis Suppurativa
Location: Johnston RI, Quebec, New York NY, Chapel Hill NC,
Sponsor: Sanofi
Sex: All
Age: 18+
Code: NCT07170917
Phase 2, Recruiting
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
for
Immune Thrombocytopenia
Location: Danvers MA, Boston MA, The Bronx NY, Albany NY,
Sponsor: Sanofi
Sex: All
Age: 18+
Code: NCT07007962
Phase 3, Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
for
Chronic Obstructive Pulmonary Disease
Location: Boston MA, Flushing NY, East Orange NJ, Philadelphia PA,
Sponsor: Sanofi
Sex: All
Age: 40 - 70+
Code: NCT07190209
Phase 3, Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
for
Chronic Obstructive Pulmonary Disease
Location: New Bedford MA, Quebec, Victoriaville, Trois-Rivieres,
Sponsor: Sanofi
Sex: All
Age: 40 - 70+
Code: NCT07190222
Phase 3, Recruiting
A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia
for
Autoimmune Haemolytic Anaemia
Location: Boston MA, Providence RI, New Haven CT, The Bronx NY,
Sponsor: Sanofi
Sex: All
Age: 18+
Code: NCT07086976
Phase 3, Recruiting
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration